BLRX
BioLineRx Ltd. NASDAQ Listed Jul 27, 2011$3.13
Mkt Cap $13.6M
52w Low $2.15
17.4% of range
52w High $7.77
50d MA $2.55
200d MA $3.23
P/E (TTM)
-9.9x
EV/EBITDA
-1.9x
P/B
0.5x
Debt/Equity
0.6x
ROE
—
P/FCF
-1.4x
RSI (14)
—
ATR (14)
—
Beta
0.48
50d MA
$2.55
200d MA
$3.23
Avg Volume
17.2K
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Modi’in Technology Park · Hevel Modi'in 7177871 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.50 | -0.34 | +32.0% | 2.32 | -0.9% | +4.3% | +2.6% | +0.4% | +2.2% | -3.0% | — |
| Nov 24, 2025 | AMC | -0.41 | -0.22 | +46.3% | 3.50 | +0.0% | +1.4% | -1.4% | -0.9% | -4.6% | -8.6% | — |
| Aug 14, 2025 | AMC | -0.35 | -1.00 | -185.7% | 3.77 | -3.2% | -1.6% | +1.6% | -0.8% | -1.9% | -4.8% | — |
| May 27, 2025 | AMC | -0.84 | 1.39 | +265.5% | 3.68 | +5.2% | +3.0% | +3.0% | +42.7% | +11.4% | +14.7% | — |
| Mar 25, 2025 | AMC | -4.20 | 6.00 | +242.9% | 3.34 | -0.3% | -5.1% | -4.5% | -8.7% | -11.4% | -12.6% | — |
| Nov 25, 2024 | AMC | -0.05 | -2.80 | -5500.0% | 10.87 | +9.8% | +1.7% | +5.6% | +9.3% | +7.3% | +3.2% | — |
| Aug 15, 2024 | AMC | -0.14 | 0.40 | +385.7% | 27.13 | +1.7% | +8.9% | +16.5% | +9.9% | +9.1% | +6.2% | — |
| May 28, 2024 | AMC | -0.29 | -0.01 | +96.6% | 28.76 | -4.5% | -4.0% | +14.0% | +3.7% | +2.1% | -2.8% | — |
| Mar 26, 2024 | AMC | -0.22 | -0.15 | +31.8% | 41.20 | +5.8% | +7.8% | +8.7% | -16.5% | -19.5% | -19.6% | — |
| Nov 20, 2023 | AMC | -7.20 | -12.00 | -66.7% | 68.00 | -5.9% | -10.6% | -10.6% | -12.4% | -14.1% | -15.9% | — |
| Aug 30, 2023 | AMC | -6.40 | -12.00 | -87.5% | 55.60 | +3.6% | +25.9% | +45.3% | +76.3% | +74.1% | +56.1% | — |
| May 24, 2023 | AMC | -5.60 | -6.00 | -7.1% | 62.40 | +0.0% | -0.6% | -3.8% | +0.6% | +1.0% | +3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.67 | $4.63 | -0.9% | -5.4% | -2.1% | -9.2% | -14.3% | -4.9% |
| May 30 | Jones Trading | Upgrade | Hold → Buy | — | $3.79 | $5.87 | +54.9% | +38.5% | +8.2% | +11.3% | +23.0% | +39.1% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.68 | $3.87 | +5.2% | +3.0% | +3.0% | +42.7% | +11.4% | +14.7% |
| Apr 2 | Jones Trading | Downgrade | Buy → Hold | — | $2.92 | $2.86 | -2.1% | +6.2% | +0.7% | -9.2% | -13.7% | -15.4% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.05 | $3.18 | +4.3% | -3.0% | -4.3% | +1.6% | -3.6% | -13.1% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.12 | $11.53 | +3.7% | -2.2% | -0.6% | +3.2% | +6.8% | +4.9% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.56 | $18.12 | +3.2% | +3.2% | +2.8% | +1.3% | +1.4% | -1.8% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.82 | $30.09 | +0.9% | -1.5% | -6.3% | -2.9% | -6.6% | -11.8% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.76 | $27.48 | -4.5% | -4.0% | +14.0% | +3.7% | +2.1% | -2.8% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.58 | $25.59 | +0.0% | -2.8% | +0.1% | +2.7% | +5.9% | -0.4% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.00 | $47.20 | -9.2% | -20.8% | -14.6% | -13.8% | -33.8% | -36.2% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.80 | $52.80 | +0.0% | +0.8% | +0.8% | +2.3% | +0.8% | -3.8% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.60 | $65.20 | -3.6% | +0.6% | -10.1% | -10.1% | -11.8% | -13.6% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $70.40 | $75.60 | +7.4% | +10.8% | +14.2% | +27.3% | +25.0% | +12.5% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.60 | $57.60 | +3.6% | +25.9% | +45.3% | +76.3% | +74.1% | +56.1% |
| May 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $62.40 | $62.40 | +0.0% | -0.6% | -3.8% | +0.6% | +1.0% | +3.8% |
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $137.60 | $136.80 | -0.6% | -3.2% | +1.7% | -6.1% | -10.2% | -8.1% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $144.80 | $111.83 | -22.8% | -21.0% | -24.6% | -27.3% | -27.1% | -27.6% |
| Nov 25 | JMP Securities | Maintains | Market Outperform → Outperform | — | $90.40 | $90.80 | +0.4% | -0.4% | +2.7% | +1.3% | +0.0% | +3.5% |
| Nov 25 | Maxim Group | Downgrade | Buy → Hold | — | $90.40 | $90.80 | +0.4% | -0.4% | +2.7% | +1.3% | +0.0% | +3.5% |
| Nov 25 | Maxim Group | Upgrade | Hold → Buy | — | $90.40 | $90.80 | +0.4% | -0.4% | +2.7% | +1.3% | +0.0% | +3.5% |
| Nov 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $90.40 | $90.80 | +0.4% | -0.4% | +2.7% | +1.3% | +0.0% | +3.5% |
| Aug 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $630.00 | $642.00 | +1.9% | +3.8% | +8.6% | +12.4% | +12.4% | +8.6% |
| May 18 | Maxim Group | Upgrade | Hold → Buy | — | $495.84 | $512.40 | +3.3% | +1.6% | +4.2% | +6.5% | +2.9% | +4.1% |
| Feb 13 | Rodman & Renshaw | Maintains | Buy → Buy | — | $654.00 | $690.00 | +5.5% | +8.3% | +3.2% | +9.2% | +16.5% | +15.6% |
| Aug 12 | Maxim Group | Downgrade | Buy → Hold | — | $525.84 | $504.00 | -4.2% | -3.0% | -1.6% | +1.6% | +5.8% | +5.0% |
| Mar 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $678.00 | $678.00 | +0.0% | +1.8% | -3.1% | -7.1% | -7.1% | -10.6% |
| Jun 22 | JMP Securities | Maintains | Outperform → Outperform | — | $1242.06 | $1338.00 | +7.7% | +3.9% | +11.6% | +9.7% | +6.3% | +23.2% |
| Jun 22 | JP Morgan | Maintains | Market Outperform → Outperform | — | $1242.06 | $1338.00 | +7.7% | +3.9% | +11.6% | +9.7% | +6.3% | +23.2% |
No insider trades available.
No recent filings available.
Data updated apr 26, 2026 9:54am
· Source: massive.com